Pau Abrisqueta

5.1k total citations
124 papers, 1.8k citations indexed

About

Pau Abrisqueta is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Pau Abrisqueta has authored 124 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 92 papers in Pathology and Forensic Medicine, 86 papers in Genetics and 45 papers in Oncology. Recurrent topics in Pau Abrisqueta's work include Lymphoma Diagnosis and Treatment (91 papers), Chronic Lymphocytic Leukemia Research (83 papers) and CAR-T cell therapy research (29 papers). Pau Abrisqueta is often cited by papers focused on Lymphoma Diagnosis and Treatment (91 papers), Chronic Lymphocytic Leukemia Research (83 papers) and CAR-T cell therapy research (29 papers). Pau Abrisqueta collaborates with scholars based in Spain, United States and United Kingdom. Pau Abrisqueta's co-authors include Francesc Bosch, Emili Montserrat, Marta Crespo, Cecilia Carpio, Andrés López, Armando López‐Guillermo, Elı́as Campo, Noelia Purroy, Eva Giné and Antonio Martı́nez and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Pau Abrisqueta

117 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Pau Abrisqueta Spain 22 1.0k 873 636 421 402 124 1.8k
Irina Bonzheim Germany 26 1.1k 1.1× 535 0.6× 948 1.5× 427 1.0× 376 0.9× 87 1.9k
Elena Hartmann Germany 26 1.5k 1.4× 1.1k 1.3× 992 1.6× 619 1.5× 675 1.7× 80 2.6k
Sergio Cogliatti Switzerland 23 1.5k 1.5× 796 0.9× 1.1k 1.7× 390 0.9× 498 1.2× 60 2.2k
Daisuke Ennishi Japan 20 958 0.9× 452 0.5× 656 1.0× 253 0.6× 289 0.7× 109 1.5k
Carla Casulo United States 19 1.3k 1.3× 555 0.6× 1.1k 1.7× 400 1.0× 244 0.6× 95 1.9k
Christian H. Geisler Denmark 25 1.8k 1.7× 1.2k 1.4× 1.1k 1.7× 512 1.2× 330 0.8× 52 2.4k
Robert Kridel Canada 21 1.4k 1.3× 593 0.7× 1.0k 1.6× 412 1.0× 482 1.2× 81 2.0k
Javier Muñoz United States 23 886 0.8× 545 0.6× 1.2k 1.9× 333 0.8× 357 0.9× 133 1.8k
Evelyne Callet‐Bauchu France 26 1.8k 1.7× 1.1k 1.3× 906 1.4× 406 1.0× 542 1.3× 62 2.6k
Manfred Hensel Germany 21 903 0.9× 988 1.1× 490 0.8× 517 1.2× 188 0.5× 68 1.6k

Countries citing papers authored by Pau Abrisqueta

Since Specialization
Citations

This map shows the geographic impact of Pau Abrisqueta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pau Abrisqueta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pau Abrisqueta more than expected).

Fields of papers citing papers by Pau Abrisqueta

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pau Abrisqueta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pau Abrisqueta. The network helps show where Pau Abrisqueta may publish in the future.

Co-authorship network of co-authors of Pau Abrisqueta

This figure shows the co-authorship network connecting the top 25 collaborators of Pau Abrisqueta. A scholar is included among the top collaborators of Pau Abrisqueta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pau Abrisqueta. Pau Abrisqueta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Morata, Jordi, Raúl Tonda, Carlos Grande, et al.. (2025). Genetic subtyping by Whole Exome Sequencing across Diffuse Large B Cell Lymphoma and Plasmablastic Lymphoma. PLoS ONE. 20(3). e0318689–e0318689.
2.
Karimi, Yasmin, Pau Abrisqueta, Sven de Vos, et al.. (2024). Epcoritamab + R-DHAX/C in transplant-eligible patients (pts) with high-risk relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).. Journal of Clinical Oncology. 42(16_suppl). 7032–7032. 7 indexed citations
3.
Falchi, Lorenzo, Joost S.P. Vermaat, Gerardo Musuraca, et al.. (2024). IBCL-278 Epcoritamab With Rituximab + Lenalidomide (R2) in Previously Untreated (1L) Follicular Lymphoma (FL) and Epcoritamab Maintenance Therapy in FL: EPCORE NHL-2 Arms 6 and 7. Clinical Lymphoma Myeloma & Leukemia. 24. S496–S497. 1 indexed citations
4.
5.
6.
Abrisqueta, Pau. (2024). New Insights into First-Line Therapy in Diffuse Large B-Cell Lymphoma: Are We Improving Outcomes?. Journal of Clinical Medicine. 13(7). 1929–1929. 5 indexed citations
7.
Abrisqueta, Pau, Lorenzo Falchi, Marcel Nijland, et al.. (2024). ABCL-272 Epcoritamab + R-DHAX/C Induces Deep, Durable Responses in Transplant-Eligible Patients With Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL), Including High-Risk Disease. Clinical Lymphoma Myeloma & Leukemia. 24. S468–S468. 1 indexed citations
8.
9.
Jiménez, Moraima, Alba Cabirta, Isabel Ruíz-Camps, et al.. (2023). Impact of COVID‐19 infection on bispecific antibodies treatment in patients diagnosed with B‐cell lymphoproliferative disorders. Hematological Oncology. 41(S2). 607–609. 1 indexed citations
10.
Abrisqueta, Pau, Daniel Medina, Guillermo Villacampa, et al.. (2022). A gene expression assay based on chronic lymphocytic leukemia activation in the microenvironment to predict progression. Blood Advances. 6(21). 5763–5773. 2 indexed citations
11.
Tazón‐Vega, Bárbara, Pau Abrisqueta, Juan C. Nieto, et al.. (2021). Immunological and genetic kinetics from diagnosis to clinical progression in chronic lymphocytic leukemia. Biomarker Research. 9(1). 37–37. 5 indexed citations
12.
Villacampa, Guillermo, Rodrigo Dienstmann, Francesc Bosch, & Pau Abrisqueta. (2021). Combination of novel molecular targeted agent plus R-CHOP-based regimen versus R-CHOP alone in previously untreated diffuse large B-cell lymphoma (DLBCL) patients: a systematic review and meta-analysis.. Annals of Hematology. 100(12). 2969–2978. 5 indexed citations
13.
Blanco, Gonzalo, Anna Vardi, Anna Puiggros, et al.. (2018). Restricted T cell receptor repertoire in CLL-like monoclonal B cell lymphocytosis and early stage CLL. OncoImmunology. 7(6). e1432328–e1432328. 21 indexed citations
14.
15.
16.
García‐Marco, José A., Julio Delgado, José‐Ángel Hernández‐Rivas, et al.. (2017). Actualización de las guías nacionales de consenso del Grupo Español de Leucemia Linfocítica Crónica para el tratamiento y seguimiento de la leucemia linfocítica crónica. Medicina Clínica. 148(8). 381.e1–381.e9. 2 indexed citations
17.
Abrisqueta, Pau, David W. Scott, Graham W. Slack, et al.. (2017). Observation as the initial management strategy in patients with mantle cell lymphoma. Annals of Oncology. 28(10). 2489–2495. 51 indexed citations
18.
Brown, Jennifer R., Matthew S. Davids, Jordi Rodón, et al.. (2015). Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma. Clinical Cancer Research. 21(14). 3160–3169. 45 indexed citations
19.
Baptista, Maria João, Ana Muntañola, Pau Abrisqueta, et al.. (2012). Differential Gene Expression Profile Associated to Apoptosis Induced by Dexamethasone in CLL Cells According to IGHV/ZAP-70 Status. Clinical Cancer Research. 18(21). 5924–5933. 4 indexed citations
20.
Hartmann, Elena, Verónica Fernández, Vı́ctor Moreno, et al.. (2008). Five-Gene Model to Predict Survival in Mantle-Cell Lymphoma Using Frozen or Formalin-Fixed, Paraffin-Embedded Tissue. Journal of Clinical Oncology. 26(30). 4966–4972. 85 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Irina Bonzheim Breakdown of academic impact, for papers by Elena Hartmann Breakdown of academic impact, for papers by Sergio Cogliatti Breakdown of academic impact, for papers by Daisuke Ennishi Breakdown of academic impact, for papers by Carla Casulo Breakdown of academic impact, for papers by Christian H. Geisler Breakdown of academic impact, for papers by Robert Kridel Breakdown of academic impact, for papers by Javier Muñoz Breakdown of academic impact, for papers by Evelyne Callet‐Bauchu Breakdown of academic impact, for papers by Manfred Hensel
Rankless by CCL
2026